Sensorion SAS (ALSEN) AI Stock Analysis

• Market Cap: €89.88M
• Dividend Yield: N/A
• Average Volume (3M): 540.27K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.33
• Revenue Growth: N/A
• EPS Growth: 10.87%
• Country: FR
• Employees: 63
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.05
• Shares Outstanding: 300,661,220
• 10 Day Avg. Volume: 740,129
• 30 Day Avg. Volume: 540,266
• PEG Ratio: 0.15
• Price to Book (P/B): 2.50
• Price to Sales (P/S): 27.15
• P/FCF Ratio: -8.04
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €4.00
• Price Target Upside: 1233.33% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: €0.28 ▼(-8.00% Downside)

The score is primarily constrained by ongoing net losses and negative operating/free cash flow despite a relatively stable, low-leverage balance sheet. Technicals also weigh on the rating with a clear downtrend and bearish momentum. Valuation is difficult to support with a negative P/E and no dividend data.

Positive Factors

Focused therapeutic pipeline

A focused pipeline targeting hearing disorders and inner ear diseases creates durable differentiation in a specialized, underserved market. Deep domain focus supports scientific expertise, clearer regulatory paths, and partnership appeal, sustaining long-term value creation despite long R&D timelines.

Low leverage, strong equity position

A healthy equity base and low leverage provide financial flexibility to fund clinical programs and absorb development volatility. This durable capital structure reduces refinancing risk, supports long-term trial investment, and preserves optionality for partnerships or strategic transactions.

Revenue growth with positive gross margin

Growing revenue and a positive gross margin indicate the company earns more than direct costs on its activities, forming a foundation for scaling. If operating costs are managed, this structural margin can translate into improving profitability as commercial efforts and partnerships mature.

Negative Factors

Persistent net losses

Continued sizeable net losses erode equity and constrain strategic flexibility. Over a 2-6 month horizon, persistent deficits raise the risk of dilution or program cutbacks, and without a clear path to operational improvement, losses threaten long-term sustainability of development plans.

Negative operating and free cash flow

Negative operating and free cash flow means core operations do not self-fund R&D or commercialization. This structural cash shortfall increases dependency on external capital, can delay trials or launches, and pressures management to prioritize financing over long-term value creation.

Reliance on financing (equity raises)

Heavy reliance on equity financing is a durable governance and capital-risk issue: repeated raises dilute shareholders and signal limited internal cash generation. If market conditions tighten, access to capital could be constrained, forcing program cutbacks or unfavorable deal terms.

Sensorion SAS Business Overview & Revenue Model

Company Description

Sensorion SA, a clinical-stage biopharmaceutical company, develops drug candidates for the treatment of inner ear disorders in France. The company develops OTOF-GT, a gene therapy development program to restore hearing in people living with Otoferlin deficiency; USHER-T1-GT, a gene therapy development program to for patients suffering from usher syndrome Type 1; and SENS-401, a drug candidate to treat sudden sensorineural hearing loss. Its pipeline also includes various products in development stage for restoring, treating, and preventing inner ear related disorders. The company has a collaboration agreement with Institut Pasteur for gene therapy program for pediatric and adult deafness; and with Sonova Holding AG to introduce genetic analysis for routine diagnosis of progressive hearing loss in adults through a combination of advanced therapeutic interventions and traditional hearing aids. Sensorion SA was founded in 2009 and is headquartered in Montpellier, France.

How the Company Makes Money

Sensorion SAS generates revenue through multiple streams, primarily from the development and commercialization of its therapeutic products. The company engages in partnerships and collaborations with pharmaceutical firms and research institutions, which often involve upfront payments, milestone payments, and royalties on future sales of products developed through these alliances. Additionally, Sensorion may receive funding through grants and public subsidies aimed at supporting medical research and development in the field of hearing disorders. These strategic partnerships and funding opportunities contribute significantly to the company's financial stability and growth potential.

Sensorion SAS Financial Statement Overview

Summary

Sensorion SAS shows potential with revenue growth and a solid equity base. However, substantial net losses and negative cash flows present significant challenges. The company needs to focus on cost control and operational efficiency to improve profitability and cash flow stability.

Income Statement

Sensorion SAS has experienced revenue growth, but profitability remains a concern. While total revenue increased from the previous year, the company continues to operate at a significant net loss. The gross profit margin is positive, indicating effective revenue management, but negative EBIT and EBITDA margins reflect high operational costs. The consistent net loss indicates a need for improved cost management and revenue enhancement strategies.

Balance Sheet

The company maintains a strong equity position with a low debt-to-equity ratio, suggesting financial stability. Stockholders' equity has improved significantly, indicating investor confidence and capital raising success. However, the persistent net losses continue to erode equity value. The equity ratio is healthy, reflecting a strong capital structure, but ongoing losses could pose risks if not addressed.

Cash Flow

Sensorion SAS exhibits a challenging cash flow position with negative operating and free cash flows. Despite generating significant financing cash flow, largely from equity raises, the company has been unable to generate positive free cash flow. The free cash flow to net income ratio remains negative, reflecting ongoing operational challenges. A focus on improving operating cash flow is essential for long-term financial health.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	5.84M	6.65M	5.70M	4.93M	4.26M	2.35M
Gross Profit	5.84M	6.65M	3.79M	4.16M	3.75M	1.94M
EBITDA	-30.40M	-27.58M	-21.33M	-22.44M	-17.46M	-10.26M
Net Income	-28.09M	-25.97M	-22.06M	-23.21M	-15.14M	-8.98M
Balance Sheet
Total Assets	73.34M	89.28M	46.50M	38.93M	59.02M	67.87M
Cash, Cash Equivalents and Short-Term Investments	57.06M	76.98M	36.97M	26.20M	50.00M	62.17M
Total Debt	1.55M	2.20M	2.87M	3.76M	3.99M	3.88M
Total Liabilities	16.36M	17.14M	13.23M	17.06M	15.03M	9.52M
Stockholders Equity	56.98M	72.14M	33.27M	21.87M	43.98M	58.35M
Cash Flow
Free Cash Flow	-28.83M	-22.45M	-21.94M	-22.92M	-11.81M	-5.48M
Operating Cash Flow	-28.28M	-21.33M	-21.07M	-21.41M	-10.77M	-5.31M
Investing Cash Flow	-11.15M	-11.13M	-381.06K	-1.54M	-1.07M	-164.93K
Financing Cash Flow	-1.20M	62.26M	32.20M	-820.68K	-715.07K	37.23M

Sensorion SAS Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.30
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALSEN, the sentiment is Negative. The current price of 0.3 is below the 20-day moving average (MA) of 0.32, below the 50-day MA of 0.33, and below the 200-day MA of 0.34, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 42.93 is Neutral, neither overbought nor oversold. The STOCH value of 20.10 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:ALSEN.

Sensorion SAS Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NANO	49 Neutral	€894.17M	―	―	―	―	―
OSE	49 Neutral	€107.71M	-3.03	-52.76%	―	-96.92%	-175.84%
MAAT	48 Neutral	€96.76M	-2.40	―	―	52.55%	-5.97%
ALSEN	47 Neutral	€89.88M	-3.20	-40.00%	―	―	10.87%
IPH	47 Neutral	€141.12M	-2.74	-271.32%	―	-75.86%	-30.54%
TNG	43 Neutral	€260.21M	-3.41	―	―	111.76%	-22.45%